Holen Sie sich die Stockscreener-App
0.5595
0.09%
0.0005
Schlusskurs vom Vortag:
$0.559
Offen:
$0.5615
24-Stunden-Volumen:
140.75K
Relative Volume:
0.73
Marktkapitalisierung:
$1.79M
Einnahmen:
$232.00K
Nettoeinkommen (Verlust:
$-12.13M
KGV:
-0.0625
EPS:
-8.9454
Netto-Cashflow:
$-10.29M
1W Leistung:
-24.38%
1M Leistung:
-36.42%
6M Leistung:
+0.00%
1J Leistung:
+0.00%
1-Tages-Spanne:
$0.5109
$0.567
1-Wochen-Bereich:
$0.5109
$0.7999
52-Wochen-Spanne:
$0.5109
$1.1996
Valion Bio Inc Stock (VBIO) Company Profile
Firmenname
Valion Bio Inc
Sektor
Branche
Telefon
(888)276-6888
Adresse
1305 E. HOUSTON STREET, SAN ANTONIO
Compare VBIO vs MOBBW, SHMD, GOODO, PSNYW, DWLD
| Aktien | Preis | Marktkapitalisierung | Umsatz | Nettogewinn | Free Cashflow | ENV |
|---|---|---|---|---|---|---|
| 0.00 | 0 | 0 | 0 | 0 | 0.00 | |
MOBBW
Mobilicom Limited Warrants
|
2.45 | 3.33B | 0 | 0 | 0 | 0.00 |
SHMD
Schmid Group N V
|
6.19 | 397.06M | 52.15M | -21.46M | 0 | -0.4675 |
GOODO
Gladstone Commercial Corporation
|
20.19 | 372.90M | 0 | 0 | 0 | 0.00 |
PSNYW
Polestar Automotive Holding Uk
|
2.83 | 254.39M | 2.07B | -1.42B | -1.37B | -0.6765 |
DWLD
Davis Select Worldwide ETF
|
47.19 | 0 | 0 | 0 | 0 | 0.00 |
Valion Bio Inc Aktie (VBIO) Neueste Nachrichten
VBIO Price Today: Valion Bio, Inc. Stock Price, Quote & Chart | MEXC - MEXC
Valion Bio's Initiative for Radiation Protection Solutions - GuruFocus
House committee directs Pentagon plan for radiation drugs By Investing.com - Investing.com Australia
House committee directs Pentagon plan for radiation drugs - Investing.com UK
Congress presses for radiation drugs that work before and after exposure - Stock Titan
Valion Bio (NASDAQ: VBIO) Confirms U.S. House Armed Services Committee Initiative to Address Urgent Need for Radiation /Nuclear Countermeasures - Sahm
Valion Bio (NASDAQ: VBIO) investors approve major equity plan boost and share issuances - Stock Titan
Valion Bio (VBIO) Stock Analysis Report | Financials & Insights - Benzinga
VBIO News | VALION BIO INC (NASDAQ:VBIO) - ChartMill
VBIO Stock Price, Quote & Chart | VALION BIO INC (NASDAQ:VBIO) - ChartMill
VBIO SEC FilingsValion Bio Inc 10-K, 10-Q, 8-K Forms - Stock Titan
Valion Bio (VBIO) CEO converts 2,206 RSUs, now holds 11,030 shares - Stock Titan
Quest Diagnostics Declares Quarterly Cash Dividend - Weekly Voice
Valion radiation drug, oral option in joint US defense, BARDA briefing - Stock Titan
Valion Bio outlines end-2026 Entolimod GMP validation target as NIAID funds GI-ARS BLA-enabling work - MSN
Valion Bio subsidiary secures exclusive NMR platform license By Investing.com - Investing.com Australia
Valion Bio (VBIO) Reports Financial Position and Strategic Focus for 2026 - GuruFocus
Valion Bio's Velocity Bioworks Secures Exclusive Commercial Lice - GuruFocus
VBIO Technical Analysis & Stock Price Forecast - Intellectia AI
VBIO PE Ratio & Valuation, Is VBIO Overvalued - Intellectia AI
VBIO Should I Buy - Intellectia AI
VALION BIO REPORTS FIRST QUARTER 2026 FINANCIAL RESULTS - GuruFocus
Valion Bio Reports Q1 2026 Earnings and Strategic Outlook - Intellectia AI
Valion Bio Reports Q1 Results, Advances Entolimod Platform - TipRanks
Valion Bio, Inc. Common Stock Q1 2026 Earnings Call Transcript - MarketBeat
Valion Bio, Inc. 1Q 2026: Revenue $24K, Net loss $(6.20M), EPS $(2.23) — 10-Q Summary - TradingView
Valion Bio, Inc. Reports Earnings Results for the First Quarter Ended March 31, 2026 - marketscreener.com
[10-Q] Valion Bio, Inc. Quarterly Earnings Report - Stock Titan
VBIO: Velocity Bioworks launch and federally funded entolimod development drive 2026 growth outlook - TradingView
Valion Bio subsidiary secures exclusive NMR platform license - Investing.com
Transcript : Valion Bio, Inc., Q1 2026 Earnings Call, May 14, 2026 - marketscreener.com
Valion Bio Q1 2026 Earnings Call: Complete Transcript - Benzinga
Valion Bio reports first quarter 2026 financial results - marketscreener.com
Valion Bio Reports First Quarter 2026 Financial Results - TradingView
Valion Bio (VBIO) widens Q1 2026 loss as it builds TLR5 and CDMO platform - Stock Titan
Valion Bio's Velocity Bioworks Secures Exclusive Commercial License to LarmorBio's BioScan-NMR™ Platform - PR Newswire
Valion Bio Inc (VBIO) Earnings Calendar_Earnings Forecast_Financial Report and Earnings Call - Tiger Brokers
Valion Bio (VBIO.US) will release its earnings report after the market closes on May 14. - Moomoo
Valion Bio to Report First Quarter 2026 Financial Results on May 14, 2026 - Morningstar
VBIO Stock Chart | VALION BIO INC (NASDAQ:VBIO) - ChartMill
3i group (TIVC) files amendment showing 9.99% holding and convertible exposure - Stock Titan
Number of shareholders of Valion Bio, Inc. – NASDAQ:VBIO - TradingView
New San Antonio plant brings 45 jobs, backs radiation drug - Stock Titan
Valion Bio Celebrates Grand Opening of Velocity Bioworks Biomanufacturing Facility in San Antonio, Anchoring Domestic Production of Entolimod™ - Barchart
Valion Bio Appoints Melinda Lackey as General Counsel - The Globe and Mail
Finanzdaten der Valion Bio Inc-Aktie (VBIO)
Umsatz
Nettogewinn
Free Cashflow
ENV
Valion Bio Inc-Aktie (VBIO) Insiderhandel
| Insiderhandel | Beziehung | Datum | Transaktion | Kosten | #Aktien | Wert ($) | #Aktien Gesamt |
|---|---|---|---|---|---|---|---|
| Valauri Christina Rizopoulos | Director |
Apr 01 '26 |
Buy |
0.95 |
19,000 |
18,008 |
19,000 |
1.27%
1.43%
In Yahoo öffnen
|
In Google öffnen
|
In Finviz öffnen
|
In MarketWatch öffnen
|
Öffnen Sie in EDGAR
|
Offen in Reuters
Kapitalisierung:
|
Volumen (24h):